Overview
Waterhouse-Friderichsen syndrome, often associated with meningococcemia, is characterized by severe sepsis leading to adrenal insufficiency, disseminated intravascular coagulation (DIC), and purpura fulminans, resulting in multiorgan failure and potential limb loss. 17Diagnosis
Clinical Presentation: Abrupt onset of purpura, hypotension, multiorgan failure, and shock.
Laboratory Findings: Severe acquired protein C deficiency, elevated inflammatory markers, and evidence of DIC.
Imaging: May show signs of organ ischemia or infarction.
Pathogen Identification: Neisseria meningitidis confirmed via blood cultures or PCR. 17Management
Antibiotics: Broad-spectrum coverage, such as meropenem 1 g IV every 12 hours in patients undergoing continuous venovenous hemodiafiltration. 2
Hemostatic Support: Protein C replacement therapy to address coagulopathy and cytokine storm. 1
Reperfusion Therapy: Recombinant tissue plasminogen activator for microvascular thrombosis and improved perfusion. 3
Supportive Care: Aggressive hemodynamic support, including vasopressors and inotropes, and organ support measures as needed.
Monitoring: Frequent assessment of organ function, coagulation parameters, and metabolic status. 13Special Populations
Pediatrics: Commonly affected; requires vigilant monitoring and early intervention to prevent complications like limb amputations. 4
Comorbidities: Patients with complement deficiencies (e.g., C7 deficiency) may have increased susceptibility to severe meningococcemia post-trauma. 6Key Recommendations
Initiate protein C replacement therapy in patients with severe meningococcemia, purpura fulminans, and multiorgan failure to improve outcomes. (Evidence: Moderate 1)
Use meropenem 1 g IV every 12 hours for antibiotic therapy in patients undergoing continuous venovenous hemodiafiltration. (Evidence: Weak 2)
Consider recombinant tissue plasminogen activator for patients with microvascular thrombosis and poor perfusion despite standard supportive care. (Evidence: Weak 3)
Closely monitor and manage coagulopathy and organ perfusion in pediatric patients due to high risk of complications like limb amputations. (Evidence: Expert opinion 4)
Screen for complement deficiencies in patients with recurrent or severe meningococcal infections, especially post-traumatic cases. (Evidence: Expert opinion 6)References
1 White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000. link
2 Meyer MM, Munar MY, Kohlhepp SJ, Bryant RE. Meropenem pharmacokinetics in a patient with multiorgan failure from Meningococcemia undergoing continuous venovenous hemodiafiltration. American journal of kidney diseases : the official journal of the National Kidney Foundation 1999. link70236-2)
3 Aiuto LT, Barone SR, Cohen PS, Boxer RA. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Critical care medicine 1997. link
4 Genoff MC, Hoffer MM, Achauer B, Formosa P. Extremity amputations in meningococcemia-induced purpura fulminans. Plastic and reconstructive surgery 1992. link
5 Morier P. Chronic meningococcemia. Dermatologica 1990. link
6 Molad Y, Zimran A, Sidi Y, Pinkhas J. Post-traumatic meningococcemia in a patient with deficiency of the C7 complement component. Israel journal of medical sciences 1990. link
7 Bernad PG, Snyder DA, Levey M. A civilian case of fatal meningococcemia due to Neisseria meningitidis, group Y. American journal of clinical pathology 1977. link